{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:19:52Z","timestamp":1768947592921,"version":"3.49.0"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The combination of hepatic arterial infusion chemotherapy (HAIC) with immune checkpoint inhibitors (ICIs) and anti-angiogenic agents represents a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). This study aimed to compare the efficacy and safety of triple therapies combining HAIC with ICIs and either bevacizumab or tyrosine kinase inhibitors (TKIs) in these patients. Methods: This retrospective single-center study enrolled 65 consecutive patients with advanced HCC who received HAIC combined with ICIs plus either bevacizumab (bevacizumab group, n = 31) or TKIs (TKIs group, n = 34) between June 2021 and June 2023. Primary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety profiles. Results: The bevacizumab group demonstrated significantly prolonged median PFS (10.9 vs. 7.4 months, p = 0.001) and higher ORR (83.9% vs. 61.8%, p = 0.047) compared with the TKIs group. DOR was longer in the bevacizumab group (7.9 vs. 5.3 months, p = 0.008). Median overall survival (OS) was not reached in the bevacizumab group versus 22.6 months in the TKIs group. Grade 3\u20134 adverse events occurred in 67.7% of the bevacizumab group and 73.5% of the TKIs group, with distinct toxicity profiles. Gastrointestinal hemorrhage (45.2%) and gastric ulcer (22.6%) predominated in the bevacizumab group, whereas the TKIs group exhibited more hepatic enzyme elevations (aspartate aminotransferase, 67.6%; alanine aminotransferase, 61.8%), proteinuria (29.4%), diarrhea (26.5%), hand-foot syndrome (20.6%), and reactive cutaneous capillary endothelial proliferation (11.8%). Conclusions: Bevacizumab-containing triplet therapy was associated with improved tumor control and delayed progression compared to TKIs-based regimens in advanced HCC. The higher bleeding risk in the bevacizumab group highlights the necessity of standardized baseline evaluation and adequate preventive measures.<\/jats:p>","DOI":"10.3390\/cancers18020314","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:36:33Z","timestamp":1768898193000},"page":"314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of HAIC Combined with PD-(L)1 Inhibitors and Bevacizumab Versus HAIC with PD-(L)1 Inhibitors and TKIs in Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Zizhuo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6353-9946","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songlin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-9957","authenticated-orcid":false,"given":"Jiacheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Kan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan 430023, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430023, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41571-023-00812-8","article-title":"Novel ICI-TKI combination improves HCC outcomes","volume":"20","author":"Killock","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","article-title":"FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2018","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99068","DOI":"10.4251\/wjgo.v17.i3.99068","article-title":"Current Research Status and Future Directions of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma","volume":"17","author":"Chisthi","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000521596","article-title":"Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements","volume":"11","author":"Sun","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3892\/ol.2023.14121","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Oncol. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tan, Z., Zhang, J., Xu, L., Wang, H., Mao, X., Zou, R., Wang, Q., Han, Z., Di, Z., and Wu, D. (2023). Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0290644"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Li, H., Si, T., Li, R., Xie, X., Liu, Y., Fu, L., Bai, Y., Yao, J., Zhang, X., and Yang, M. (2025). Hepatic Arterial Infusion Chemotherapy with Serplulimab and the Bevacizumab Biosimilar HLX04 for Advanced Hepatocellular Carcinoma: A Prospective, Observational Phase II Clinical Trial. Cancers, 17.","DOI":"10.3390\/cancers17193235"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): A phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103535","DOI":"10.1016\/j.inffus.2025.103535","article-title":"Multi-Period Prediction of Residual Lung Lesions in COVID-19 Survivors with Multi-Head Temporal Constrained Network","volume":"126","author":"Han","year":"2026","journal-title":"Inf. Fusion"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41416-023-02437-1","article-title":"Checkpoint Inhibitors and Anti-Angiogenic Agents: A Winning Combination","volume":"129","author":"Brest","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","article-title":"Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials","volume":"174","author":"Fulgenzi","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wu, D., Jia, B., Jia, M., Zhao, H., Zhao, H., and Zhou, J. (2023). Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1274754"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12072-023-10599-6","article-title":"Arterial Chemotherapy for Hepatocellular Carcinoma in China: Consensus Recommendations","volume":"18","author":"Zhao","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/annonc\/mdm528","article-title":"Hepatic Arterial Infusion of Chemotherapy: The Role of Diagnostic and Interventional Radiology","volume":"19","author":"Ganeshan","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Xu, W., Li, Q., and Liang, B. (2025). Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements. Curr. Oncol., 32.","DOI":"10.20944\/preprints202503.1424.v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2214\/AJR.05.0693","article-title":"Temporary Indwelling Catheter System via the Left Brachial Artery: Evaluation in 83 Patients with Hepatic Tumors","volume":"188","author":"Nagaoka","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/ijc.35341","article-title":"Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study","volume":"156","author":"He","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JHC.S488734","article-title":"Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus","volume":"12","author":"Li","year":"2025","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12072-024-10762-7","article-title":"HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion","volume":"19","author":"Tang","year":"2025","journal-title":"Hepatol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/j.acra.2024.09.061","article-title":"Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"32","author":"Jiang","year":"2024","journal-title":"Acad. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S502350","article-title":"PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined with HAIC for Unresectable HCC: A Propensity Score Matching Study","volume":"14","author":"He","year":"2025","journal-title":"ImmunoTargets Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: An analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J. Gastroenterol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:46:10Z","timestamp":1768898770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020314"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020314","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}